When AI designs a drug, who gets the credit?

When AI designs a drug, who gets the credit? That question hangs over the work of Insilico Medicine, a biotech company that recently proposed a potential treatment for pulmonary fibrosis using its generative AI platform. The company proudly announced in a press release that the molecule had been “discovered by” its AI system, highlighting the growing role of artificial intelligence in pharmaceutical research. Yet, when it came time to file for a patent, the company took a different stance. The patent application named five individuals, including CEO Alex Zhavoronkov, as the “inventors,” making no mention of the AI model that had supposedly led to the discovery. This discrepancy underscores a critical issue in intellectual property law: while AI systems are increasingly integral to scientific breakthroughs, current legal frameworks recognize only humans as eligible for inventor status. This rule was reinforced in a recent legal case involving an AI named DABUS, which was claimed to have designed a more efficient food container. The case, brought by lawyer Ryan Abbott, challenged the notion that machines could be considered inventors. However, in 2022, an appeals court in Washington, DC, ruled that the term “inventor” refers specifically to a person, effectively dismissing the claim that an AI could hold such status. The ruling highlights a broader philosophical and legal debate about the nature of creativity and invention. While some argue that AI systems can generate novel solutions independently, others maintain that the eureka moment, a spark of insight that leads to a breakthrough, must originate from a human mind. Legal experts suggest that this distinction is crucial for maintaining the integrity of intellectual property protections. “There needs to be a human inventor or there’s no invention and no patent,” says Sarah Korman, a patent attorney and former legal officer at Isomorphic Labs. She notes that current laws may struggle to adapt to a world where AI plays an ever-greater role in discovery. Despite these legal constraints, AI continues to reshape the landscape of drug development. Companies like Insilico Medicine are leveraging machine learning algorithms to identify molecular structures that could serve as potential treatments for diseases. These models can analyze vast datasets and simulate complex biological interactions far faster than traditional methods allow. As a result, AI-driven approaches are helping researchers explore pathways that might otherwise remain hidden. Yet, the legal framework governing patents remains unchanged. According to the U.S. Patent and Trademark Office, an AI system may perform tasks that, if done by a human, would qualify as inventorship. However, the final determination still hinges on whether a human contributed significantly to the process. This creates a gray area, especially as AI becomes more autonomous in generating results. Legal scholars warn that this ambiguity could lead to disputes over the validity of AI-generated inventions, particularly if the contribution of human collaborators is unclear. In response to these evolving challenges, the U.S. government has issued guidelines aimed at clarifying when human involvement qualifies as inventorship. Under the Biden administration, the patent office encouraged transparency about the role of AI in the discovery process. However, during the Trump administration, policies shifted toward treating AI as just another tool, akin to a calculator, without requiring special recognition. This inconsistency reflects the ongoing tension between technological progress and existing legal norms. As AI continues to advance, the question of who deserves credit, and who holds the rights to the resulting discoveries, remains unresolved. For now, the law favors human inventors, but the rapid pace of AI adoption suggests that this balance may soon shift. Until then, pioneers in the field must navigate a complex legal terrain, ensuring that their innovations meet the criteria for patentability while acknowledging the pivotal role of artificial intelligence in the process.